New York, June 3, 2026, 08:04 (EDT)
Verrica Pharmaceuticals Inc. was last seen at $5.79 ahead of Wednesday’s U.S. open. Shares ended Tuesday at $5.80 on Nasdaq, off 2.2%. Traders are focused on YCANTH sales and the company’s cash runway as Verrica comes up on its June 4 investor presentation.
U.S. cash markets were still closed. Nasdaq’s main trading session is 9:30 a.m. to 4:00 p.m. Eastern, with premarket trading open from 4:00 a.m. until the bell at 9:30 a.m., but volume tends to be lower in premarket. June 3 does not appear as a 2026 market holiday, according to .
Verrica’s next public move isn’t an earnings release. CEO Jayson Rieger is set to speak at the Jefferies Global Healthcare Conference in New York on Thursday at 11:05 a.m. ET. The event, scheduled from June 2-4, brings together healthcare companies and investors.
News flow is light. Verrica’s latest site update is still the May 28 Jefferies note. That comes after its Q1 report on May 12. There’s been no new company filing or product news in the last two days.
Rieger said in May the company saw “accelerating growth in market demand for YCANTH” and was “beginning to realize the traction” from actions last year. Verrica posted first-quarter revenue of $5.0 million. That included $4.3 million in U.S. YCANTH net product revenue, a 25.4% rise from a year ago. Net loss came in at $9.7 million. GlobeNewswire
YCANTH, Verrica’s approved drug for molluscum contagiosum, targets a viral skin disease that usually hits kids. The company has YCANTH in Phase 3 testing for common warts. It is also working on VP-315, which is in development for basal cell carcinoma, a frequent type of skin cancer.
H.C. Wainwright’s Raghuram Selvaraju picked up coverage of Verrica on May 26, starting at Buy and setting a $12 target, which is more than twice where shares finished Tuesday, according to a market report. A Buy rating signals the analyst expects the stock to beat the market but doesn’t promise anything.
Stocks moved up Tuesday, and the big indexes weren’t the issue. The S&P 500 closed at a new high, while the Nasdaq Composite ended a bit higher as well, according to the Associated Press.
Focus is shifting to who controls sales channels in dermatology, rather than just molluscum competitors. Arcutis Biotherapeutics sells ZORYVE for eczema, seborrheic dermatitis, and plaque psoriasis. Organon’s VTAMA is on the market for plaque psoriasis and atopic dermatitis. Both are going after dermatologists and payers, sometimes overlapping even beyond Verrica’s main molluscum area.
But there’s a clear risk on the downside. Verrica’s 10-Q showed $20.6 million in cash at March 31 and $9.2 million spent on operations in the quarter. The filing said there was “substantial doubt” about staying in business over the next year, meaning the company doesn’t see a way to keep going without more money. SEC
The market focus in the week ahead is if Rieger will lay out specifics on YCANTH demand, the Japan partnership with Torii Pharmaceutical, and timing for the common-warts trial. Without those details, investors may stay wary about funding and the stock could continue to trade on balance-sheet risks rather than product growth.
